Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$340.31M |
$6.01
-4.30%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$338.82M |
$6.47
-1.97%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$336.36M |
$5.21
+4.20%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$333.48M |
$15.36
+0.03%
|
|
MTLS
Materialise N.V.
Materialise's Mimics platform centers on medical imaging analysis and planning workflows.
|
$333.14M |
$5.63
+0.81%
|
|
NVEC
NVE Corporation
Medical devices & biometrics applications, including implantable sensors and collaboration with Abbott.
|
$330.52M |
$68.32
+3.17%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$330.09M |
$3.29
-1.35%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$329.21M |
$11.74
-0.84%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$327.13M |
$2.03
-4.69%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$320.86M |
$6.37
-0.16%
|
|
SENS
Senseonics Holdings, Inc.
Senseonics develops and markets implantable medical devices and biometric sensing technologies (Eversense CGM), fitting the Medical Devices & Biometrics investable theme.
|
$316.10M |
$7.77
+6.88%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$314.65M |
$8.81
+0.46%
|
|
TOI
The Oncology Institute, Inc.
Company operates community clinics and infusion suites (Outpatient/ASC Operators).
|
$313.24M |
$3.35
-0.15%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$307.32M |
$14.86
-0.30%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$306.61M |
$11.69
-0.17%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$304.35M |
$8.23
+1.67%
|
|
SMLR
Semler Scientific, Inc.
QuantaFlo is a diagnostic device used to measure arterial blood flow for PAD, directly constituting Diagnostic Equipment.
|
$300.98M |
$20.34
+0.02%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$297.94M |
$5.84
+4.47%
|
|
CLLS
Cellectis S.A.
Lead assets UCART22 and UCART20x22 are allogeneic cell therapies (CAR-T) directly developed and manufactured by the company.
|
$294.36M |
$4.08
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$290.94M |
$5.39
+1.70%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
VMD
Viemed Healthcare, Inc.
Viemed operates as an in-home healthcare provider delivering home health and hospice services.
|
$284.30M |
$7.33
-2.79%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$283.83M |
$2.62
-1.69%
|
|
SLQT
SelectQuote, Inc.
Healthcare Services & Facilities encompasses SelectRx and other healthcare services provided via the platform.
|
$278.23M |
$1.60
-3.89%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$277.32M |
$4.61
+4.54%
|
|
CIA
Citizens, Inc.
Accident & health (A&H) / health insurance offerings are mentioned as part of the product mix.
|
$276.85M |
$5.51
+0.55%
|
|
SPOK
Spok Holdings, Inc.
GenA alphanumeric pager represents a medical device hardware line under Medical Devices & Biometrics.
|
$270.77M |
$13.13
-0.76%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$269.82M |
$3.40
-1.02%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$269.58M |
$12.62
-5.51%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$267.90M |
$3.12
-4.14%
|
|
SY
So-Young International Inc.
So-Young Clinic is a branded network of outpatient aesthetic centers, which is its core revenue driver.
|
$265.19M |
$2.67
+0.94%
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is a gene therapy using autologous cells, placing Abeona in the gene therapy space.
|
$260.49M |
$5.05
-0.49%
|
|
QSI
Quantum-Si incorporated
The company manufactures diagnostic-grade hardware instruments (Platinum/Proteus) used for proteomics analysis.
|
$257.17M |
$1.28
+4.07%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
HBB
Hamilton Beach Brands Holding Company
Medical devices & biometrics appropriate to HealthBeacon’s connected health offering.
|
$256.32M |
$19.69
-0.35%
|
|
KRMD
KORU Medical Systems, Inc.
KRMD's core business is medical devices focused on patient-centric subcutaneous infusion systems (Freedom) and related components.
|
$254.75M |
$5.52
-2.65%
|
Showing page 20 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
